U.S. Pharmacist Opinions Regarding the Rescheduling of Hydrocodone Combination Products: A Pilot Study

In October 2014, the Drug Enforcement Administration in the U.S. reclassified hydrocodone combination products (HCPs) from Schedule III to Schedule II, initiating one of the most significant and controversial regulatory changes for opioids in recent national history. The aim of the present study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Covvey, Jordan R., Pfalzgraf, Andrea R., Cohron, Peter P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597174/
https://www.ncbi.nlm.nih.gov/pubmed/28975908
http://dx.doi.org/10.3390/pharmacy3030129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597174/
https://www.ncbi.nlm.nih.gov/pubmed/28975908
http://dx.doi.org/10.3390/pharmacy3030129

Ejemplares similares